ABT Jan 2025 115.000 call
| Previous close | 3.8500 |
| Open | 3.8000 |
| Bid | 3.7000 |
| Ask | 3.9000 |
| Strike | 115.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.8000 - 3.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.61k |
- Reuters
Drugmaker Abbott India posts Q4 profit rise on higher sales
Indian drugmaker Abbott India reported a 24% rise in fourth-quarter profit on Thursday, as strong sales outpaced the impact of government pricing caps on certain medicines. Revenues of drugmakers such as Abbott India and GlaxoSmithKline Pharma India, which get most of their business from India, have been impacted after the inclusion of some of their drugs in the government's essential medicines list in September 2022, making them susceptible to price caps. Abbott, which is a unit of U.S. healthcare firm Abbott Laboratories, has been trying to mitigate the impact of pricing curbs by driving up sales and cutting back on expenses.
GuruFocus.comInsider Sale: Executive Vice President Lisa Earnhardt Sells 22,852 Shares of Abbott ...
On May 7, 2024, Lisa Earnhardt, Executive Vice President of Abbott Laboratories (NYSE:ABT), sold 22,852 shares of the company.
ZacksThe Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips
Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips are included in this Analyst Blog.
